Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.86 |
| ▸ | BRAF | P15056 | 2/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12416823 | 0.93 | GRM5 (1.00) | GRM5BRAFCSF1RCYP11B1CYP11B2 | |
| SCHEMBL12412778 | 0.90 | GRM5 (0.84) | GRM5BRAF | |
| SCHEMBL12411962 | 0.89 | GRM5 (0.70) | GRM5BRAFCSF1RALDH1A1 | |
| SCHEMBL12412757 | 0.89 | GRM5 (0.79) | GRM5BRAFCSF1RCYP11B1CYP11B2 | |
| SCHEMBL12412768 | 0.87 | GRM5 (0.72) | GRM5BRAF | |
| SCHEMBL12412771 | 0.87 | GRM5 (0.72) | GRM5BRAFCSF1R | |
| SCHEMBL12412764 | 0.87 | GRM5 (0.71) | GRM5BRAFCSF1RCYP11B1CYP11B2 | |
| SCHEMBL12411966 | 0.84 | GRM5 (0.66) | GRM5BRAFCSF1R | |
| SCHEMBL12412773 | 0.84 | GRM5 (0.68) | GRM5BRAF | |
| SCHEMBL15847396 | 0.84 | BRAF (0.77) | GRM5BRAFCYP11B1CYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501757-B2 | Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501757-B2 | Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | GRM5 1/4885BRAF 3421/4885CSF1R 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.